NantKwest appoints Fred Driscoll to board
Joining NantKwest’s Board, Mr. Driscoll brings more than 30 years of deep financial and commercialization experience in the biotechnology and medical device industries.
Prior to joining NantKwest, Mr. Driscoll has been an Advisor of Flexion Therapeutics, Inc. and served as the Chief Financial Officer of Flexion Therapeutics, Inc. from 2013 until his retirement earlier this year.
Prior to Flexion, he served as the Chief Financial Officer, Vice President, Treasurer and Principal Accounting Officer of Novavax, Inc.
He served as the Chief Executive Officer and President at Genelabs Technologies, Inc. and also served as its Chief Financial Officer.
Earlier in his career, Mr. Driscoll was Chief Financial Officer of Astraris, Inc., Chief Executive Officer and President of OXiGENE, Inc., and Senior Vice President of Finance and Operations of Collagenesis Corporation.
He has more than 30 years of financial management experience with biotechnology and medical device companies.
Mr. Driscoll has a Bachelor’s degree in Accounting and Finance from Bentley University in Waltham, Massachusetts. ■
LATEST MOVES FROM California
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
- Amyris appoints Eduardo Alvarez as COO
- ChromaDex appoints Kevin Farr as CFO
- Apple appoints Katherine Adams as general counsel, SVP
More inside POST